New peanut allergy treatment now in clinical trials

May 23, 2017, Monash University
New peanut allergy treatment now in clinical trials
L-R: Dr Sara Prickett, Professor Robyn O’Hehir and Emeritus Professor Jenny Rolland have worked together for years on the peanut allergy research and are co-founders of Aravax P/L. Credit: Monash University

A new peanut allergy treatment developed by Monash researchers is now beginning clinical trials in Melbourne and Adelaide.

Professor Robyn O'Hehir is Professor/Director of the Department of Allergy, Immunology and Respiratory Medicine at Alfred Health and Monash University. Her research team, co-led by Professor Jennifer Rolland, identified the critical components of the allergy therapy now being developed by Aravax, an Australian spinout biotechnology company.

The technology uses carefully selected fragments of peanut proteins to switch off . The product is designed to be safer, more rapid, and more convenient than other approaches currently under development. The Aravax team anticipates that simple, monthly injections will be sufficient to achieve clinical benefit.

Dr Pascal Hickey, CEO of Aravax, said the team wants to help people around the world who suffer from peanut allergy to live stress-free lives without constantly fearing a major health event from accidental consumption.

"Our technology aims to alleviate that stress by reprogramming the immune system to tolerate peanuts. By creating a safe, convenient and fast solution to a very serious problem we believe our product will have a global health impact by transforming the lives of patients and their carers," Dr Hickey said.

Almost two in every hundred Australians suffer from peanut allergy, and currently there is no therapy to reduce the severity of allergic reactions that can occur following accidental consumption. Despite patients attempting to follow a peanut-free diet, every year around 40 per cent of peanut allergic individuals will suffer a serious adverse event from inadvertent exposure, including anaphylaxis which can lead to death.

Traditionally, allergy specialists have treated patients using repeated doses of the -causing substance. Similar approaches are being explored to treat , but the use of preparations containing whole carries a high risk of severe reactions and requires daily dosing for lengthy periods. Aravax's product is different because it does not contain the parts of peanut protein that cause severe allergic reactions, and its once-a-month dosing regimen is a far simpler solution than remembering to take medication every day.

In the first ever trial of its product known as PVX108, Aravax will evaluate the safety and tolerability of single and repeated administration across a wide range of doses to determine an appropriate dosing regimen. This double-blinded and placebo controlled trial commenced dosing on 10 May 2017 with the first group of subjects safely receiving the lowest dose of PVX108. The trial is being conducted at CMAX Clinical Research in Adelaide, and at Nucleus Network in Melbourne.

Professor O'Hehir said the research has been supported by the Australian Food Allergy Foundation, the Alfred Hospital Trust, and the National Health and Medical Research Council.

"In 2015, we secured AUD $4.85M from the Medical Research Commercialisation Fund (MCRF) to develop the technology through to initial clinical . What is really exciting about this is not only the opportunity we have to get our therapeutic product up and running to protect the many sufferers, but that Australian is being funded in Australia for development to clinical trial," Professor O'Hehir said.

Explore further: Oral immunotherapy is safe, effective for peanut-allergic preschoolers, study suggests

More information: Peanut allergy sufferers interested in participating in the trials can contact Aravax for further information. www.aravax.com.au/product-development.html

Related Stories

Oral immunotherapy is safe, effective for peanut-allergic preschoolers, study suggests

August 10, 2016
Nearly 80 percent of peanut-allergic preschool children successfully incorporated peanut-containing foods into their diets after receiving peanut oral immunotherapy (OIT), a clinical trial has found. Peanut OIT involves eating ...

Anaphylaxis risk up for siblings of peanut allergic children

June 14, 2016
(HealthDay)—The risk of anaphylaxis is increased upon peanut introduction in siblings of children with peanut allergy, according to a study published online June 13 in Allergy.

Study suggests patch is safe, convenient mode of treatment for peanut allergy

October 26, 2016
A wearable patch that delivers small amounts of peanut protein through the skin shows promise for treating children and young adults with peanut allergy, with greater benefits for younger children, according to one-year results ...

Video: Why are people allergic to peanuts?

March 22, 2016
For 1 to 2 percent of the global population, eating a peanut butter and jelly sandwich could be potentially fatal. What makes peanut allergies so lethal, and why is the number of peanut-allergy sufferers on the rise?

Expert panel issues clinical guidelines to prevent peanut allergy

January 5, 2017
An expert panel sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, issued clinical guidelines today to aid health care providers in early introduction ...

Recommended for you

During HIV infection, antibody can block B cells from fighting pathogens

August 13, 2018
For the first time, scientists have shown that in certain people living with HIV, a type of antibody called immunoglobulin G3 (IgG3) stops the immune system's B cells from doing their normal job of fighting pathogens. This ...

Link between common 'harmless' virus and cardiovascular damage

August 13, 2018
Researchers from Brighton and Sussex Medical School (BSMS) have found an unexpectedly close link between a herpes virus and the occurrence of immune cells damaging cardiovascular tissue.

Single transplantation of therapeutic macrophages improves rare lung disease in mice

August 9, 2018
Hereditary pulmonary alveolar proteinosis (herPAP) is a rare disease characterized by the slow build-up of lipo-protein material in the lungs due to the failure of highly specialized cells called macrophages, which usually ...

New antibody analysis accelerates rational vaccine design

August 8, 2018
A team at Scripps Research has come up with a faster way to analyze the outcome of experimental vaccines against HIV and other pathogens. Their new system lets scientists quickly assess the full spectrum of antibodies produced ...

New immune defenders added to blood cell

August 7, 2018
Our researchers have revealed the identities of new subsets of immune cells at the frontline of our body's defenses against infection.

Striking a balance between immunity and inflammation

August 6, 2018
Hookworms infect nearly 430 million people in the world, mostly in countries where sanitation is poor, and people often walk barefoot.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.